Top Industry Leaders in the Blepharitis Market
Latest Blepharitis Companies Update:
August 2023, the US Food and Drug Administration (FDA) approved Xdemvy (demeclocycline ophthalmic ointment) for the treatment of Demodex blepharitis. This is the first-ever FDA approved drug for this specific type of blepharitis, which is caused by microscopic mites called Demodex.
Xdemvy is expected to be a significant market driver, as it offers a new and effective treatment option for Demodex blepharitis patients.
January 2023, Bausch + Lomb acquired AcuFocus, a company developing innovative ophthalmic technologies. This acquisition gives Bausch + Lomb access to AcuFocus's pipeline of blepharitis treatments, including the IClarify™ excimer laser system for treating dry eye disease, which can be associated with blepharitis. This acquisition is expected to strengthen Bausch + Lomb's position in the blepharitis market and allow them to offer a wider range of treatment options.
List of Blepharitis Key companies in the market
- Scope Ophthalmics Ltd
- Novartis AG
- InSite Vision Incorporated
- Thea Pharmaceuticals Limited
- Galderma S.A.
- NovaBay Pharmaceuticals, Inc.
- Merck & Co.
- Perrigo Laboratories